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Abstract
Background: Tenofovir disoproxil fumarate, a prodrug of the nucleotide reverse transcriptase
inhibitor, tenofovir (9-[9(R)-2-(phosphonomethoxy)propyl]adenine; PMPA), was recently
approved for use in the combination therapy of human immunodeficiency virus (HIV)-1 infection.
This study was undertaken to understand PMPA distribution to the virus sanctuary sites located in
the brain, CSF and choroid plexuses and to clarify its possible role in reducing the neurological
problems associated with HIV infection.
Methods:  The methods used included an established bilateral carotid artery perfusion of
[3H]PMPA and a vascular marker, D-[14C]mannitol, in anaesthetised guinea-pigs followed by
scintillation counting, HPLC and capillary depletion analyses. Movement of [3H]PMPA into the
brain, cisternal CSF and lateral ventricle choroid plexus was also examined in the absence and
presence of additional anti-HIV drugs and a transport inhibitor. Control and test groups were
compared by ANOVA or Student's t-test, as appropriate.
Results: The distribution of [3H]PMPA in the cerebrum, cerebellum, pituitary gland and cerebral
capillary endothelial cells was not significantly different to that measured for D-[14C]mannitol.
However, [3H]PMPA accumulation was significantly higher than that of D-[14C]mannitol in the
choroid plexus and CSF. Further experiments revealed no cross-competition for transport of
[3H]PMPA by probenecid, a non-specific inhibitor of organic anion transport, or the nucleoside
reverse transcriptase inhibitors into any of the CNS regions studied. The octanol-saline partition
coefficient measurement for [3H]PMPA was 0.0134 ± 0.00003, which is higher that the 0.002 ±
0.0004 measured for D-[14C]mannitol in an earlier study.
Conclusion: There is negligible transport of [3H]PMPA across the blood-brain barrier, but it can
cross the blood-CSF barrier. This is a reflection of the differing physiological and functional
characteristics of the blood-CNS interfaces. Self- and cross-inhibition studies did not suggest the
involvement of a transport system in the CNS distribution of this drug. However, the ability of
PMPA to accumulate in the choroid plexus tissue, but not the cerebral capillary endothelial cells,
and the hydrophilic nature of PMPA, does point to the possibility of a transporter at the level of
the choroid plexus. PMPA that has crossed the choroid plexus and is in the CSF could treat HIV-
infected perivascular and meningeal macrophages, but it is unlikely to reach the infected microglia
of deep brain sites.
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Background
Tenofovir (9-[9(R)-2-(phosphonomethoxy)propyl]ade-
nine; PMPA) is an acyclic nucleotide analogue with potent
in vitro and in vivo antiretroviral activity. Despite its dem-
onstrated antiviral potency, tenofovir has limited oral bio-
availability in animals, presumably resulting from the
presence of two negative charges on the phosphonyl
group [1]. These observations have led to the design of a
novel oral prodrug of PMPA, tenofovir disoproxil fuma-
rate (Viread; Gilead Sciences Inc. and Figure 1). The addi-
tion of the disoproxil moiety aids oral absorption and
once in the circulation, tenofovir is rapidly liberated and
can be absorbed into cells where cellular enzymes directly
produce the active metabolite, tenofovir diphosphate.
Tenofovir diphosphate competitively inhibits human
immunodeficiency virus (HIV) reverse transcription and
causes chain termination of the nascent viral cDNA. Sev-
eral clinical trials have successfully demonstrated the effi-
cacy and favorable safety profile of tenofovir disoproxil
fumarate in HIV-infected patients [2-5] and it is approved
for use in the treatment of HIV-1 infection as a once-daily
drug in combination with other antiretroviral regimens
[6].
Highly active anti-retroviral therapy (HAART), where
three or more anti-HIV drugs are used in parallel, dramat-
ically reduces the mortality and morbidity associated with
HIV infection, and is the recommended treatment strategy
for HIV infection [7]. However, even with treatment, total
eradication of HIV-1 appears impossible [8,9]. This is due
to the presence of virus in host cellular and anatomical
reservoirs that are inaccessible to HAART, and conse-
quently are a source of viral rebound to the plasma if ther-
apy is discontinued or inadequate [10-12]. A number of
different cellular reservoirs of HIV have been identified,
these include: CD4+  T cells [8,13,14], macrophages
[15,16] and follicular dendritic cells [17]. The key ana-
tomical viral reservoirs are the central nervous system
(CNS), lymphoid organs [18] and the genitourinary tract
[10,11]. The presence of HIV within the brain and CSF is
directly associated with the development of a syndrome
called HIV-associated dementia (HAD), which is charac-
terized by a collection of cognitive, motor and behav-
ioural symptoms [19]. In order to reduce the occurrence
of HAD, therapeutic concentrations of antiviral drugs
must reach the CNS. In support of this, it has been dem-
onstrated that drugs which are able to reach the CSF,
improve CNS function in HIV-infected individuals, as
measured by psychomotor testing, a sensitive predictor of
HAD [20,21]. Furthermore, sub-therapeutic levels of anti-
HIV agents within the CNS may permit the evolution of
drug resistant viral strains in the CSF, which have the
potential to re-infect the periphery [11]. Several studies
have provided evidence for the development of drug
resistant HIV strains in the CSF independently of the
plasma [22-24]. The presence of drug resistant variants of
HIV is a major clinical concern as it is associated with ther-
apy failure, disease progression and death. A clear under-
standing of drug distribution into these cellular and
anatomical reservoirs is consequently of interest and
could aid the rationale design of drug combinations to
treat HIV infection more effectively. Entry of anti-HIV
drugs into the CNS is partly limited by the blood-brain
barrier (BBB) located at the cerebral capillary endothe-
lium, and the blood-CSF barrier found at the choroid
plexuses and the arachnoid membrane. This study focuses
on the distribution of PMPA to the CNS by means of a
brain/choroid plexus perfusion technique in anaesthe-
tised guinea-pigs.
Methods
Brain perfusion technique
All the experiments were authorized under the Scientific
Procedures Act (UK, 1986). Adult guinea-pigs (B & K,
Grimston Hull, UK), n = 45, were anaesthetized with 0.32
mg/kg fentanyl and 10 mg/kg fluanisone (Hypnorm;
Jansenn Animal Health, High Wycombe, UK) and 5 mg/
kg midazolam (Hypnovel, Roche, Switzerland) intraperi-
toneally. They were heparinised with 25,000 units
heparin sodium/ml, 1 ml/kg by the same route. The com-
mon carotid arteries were cannulated with fine silicon
tubing connected to a perfusion pump as previously
described [25]. The perfusion fluid consisted of an artifi-
cial plasma (NaCl 117.0 mM, KCl 4.7 mM, MgSO4 0.8
mM, NaHCO3 24.8 mM, KH2PO4 1.2 mM, CaCl2·6H2O
2.5 mM, D-glucose 10 mM, dextran MW 60 000–90 000
(MP Biochemicals, Aurora, OH, USA) 39 g/L and bovine
serum albumin 1 g/L), which had been thoroughly oxy-
genated, debubbled and warmed to 37°C before passing
into each carotid artery. With the start of perfusion, the
jugular veins were sectioned and [3H]PMPA and D-
[14C]mannitol dissolved in the artificial plasma could be
infused into the inflowing perfusion medium via a slow
drive syringe pump. Final concentrations in the perfusion
medium were 6.5 nM for [3H]PMPA and 0.96 µM for D-
Structure of tenofovir disoproxil fumarate Figure 1
Structure of tenofovir disoproxil fumarate.Cerebrospinal Fluid Research 2006, 3:1 http://www.cerebrospinalfluidresearch.com/content/3/1/1
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[14C]mannitol. After varying perfusion times ranging
from 2.5 to 30 min, a cisterna magna CSF sample was
taken and the animal decapitated.
Scintillation counting and capillary depletion analysis
Cerebrum, cerebellum, pituitary gland, lateral ventricle
choroid plexuses, CSF and plasma samples were prepared
for radioactive liquid scintillation counting by the addi-
tion of tissue solubiliser (Solvable; Packard Berkshire,
UK) and liquid scintillation fluid (Lumasafe: Packard).
Cerebrum samples were also taken for capillary depletion
analysis by dextran density centrifugation as previously
reported [25]. This method determines if a drug has actu-
ally crossed the BBB as it examines drug accumulation by
the cerebral capillary endothelial cells and ensures any
drug accumulation in the brain is not just a consequence
of drug being trapped within the cerebral capillary
endothelium. In brief, approximately 500 mg of cerebrum
was homogenised in a glass homogeniser with 1.5 ml cap-
illary depletion solution (HEPES 100 mM; NaCl 141 mM;
KCl 4 mM; CaCl2·2H2O 2.8 mM; MgSO4·3H2O 1 mM;
NaH2PO4·2H2O 1 mM; D-glucose 10 mM) before the
addition of 2 ml dextran solution (26% w/v in water) and
further homogenisation. Duplicate samples of this
homogenate were taken, and the remainder was separated
into two microcentrifuge tubes and centrifuged for 15 min
(5400 g, 4°C). The resulting supernatant consisting of the
brain parenchyma and the pellet rich in cerebral capillar-
ies were separated, and together with the whole brain
homogenate samples, prepared for liquid scintillation
counting as described above.
Self- and cross-inhibition experiments
Brain/choroid plexus perfusions were also carried out
with the addition of 50 µM unlabelled PMPA, 100 µM azi-
dodeoxythymidine (AZT), 100 µM 2',3'-didehydro-3'-
deoxythymidine (D4T), 100 µM 2'3'-dideoxycytidine
(ddC) or 100 µM abacavir in the artificial plasma. A fur-
ther inhibitor study used 350 µM unlabelled probenecid,
which is a broad inhibitor of organic anion transport, in
the perfusion medium. All inhibitor studies had a per-
fusion time of 20 min.
Expression of results
The amount of radioactivity in all the tissue samples was
expressed as a percentage of the radioactivity in the
plasma and termed uptake (%). When necessary,
[3H]PMPA uptake was corrected for D-[14C]mannitol
space by subtracting the D-[14C]mannitol uptake from the
[3H]PMPA uptake.
HPLC/radio detector analysis
The integrity of the tritium label to PMPA and the stability
of PMPA in the artificial plasma were determined by
HPLC/radio detector analysis. Samples were taken from
The uptake of [3H]PMPA and D-[14C]mannitol into the dif- ferent CNS regions measured against perfusion time Figure 2
The uptake of [3H]PMPA and D-[14C]mannitol into the dif-
ferent CNS regions measured against perfusion time. Data at 
each time point represents mean ± S.E.M., n = 3–8. When 
the uptake of [3H]PMPA was significantly greater than that 
for D-[14C]mannitol the level of significance is indicated. Else-
where there was no significant difference between [3H]PMPA 
and D-[14C]mannitol in that tissue compartment at that time 
point.
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the artificial plasma both before (arterial inflow) and after
(venous outflow) it had passed through the cerebral circu-
lation. Venous outflow samples were collected after the
brains had been perfused for 5 and 25 min. The presence
of intact [3H]PMPA in samples of the arterial inflow and
venous outflow was determined by counter-ion reverse
phase chromatography with radioactive flow detection
(modified from [1]). Samples were prepared for analysis
as follows. Venous outflow, collected after 5 or 25 min of
perfusion, was centrifuged (3000 g, 5 min 4°C, Denley
BR401 refrigerated centrifuge, Billingshurts, West Sussex,
UK) and 75 µl of the supernatant was placed in a micro-
centrifuge tube, to which 75 µl acetonitrile was added
before vortexing and centrifugation (13,000 g, 5 min,
4°C). The supernatant was then removed and diluted
with HPLC grade water to achieve a final acetonitrile con-
centration of less than 10%. The sample was then
lyophilised with N2 to a suitable volume for HPLC analy-
sis. Samples of the arterial inflow were diluted 1:1 with
acetonitrile and prepared for HPLC analysis in an identi-
cal manner. The HPLC system comprised of HG-1580
high pressure, high performance gradient HPLC solvent
delivery system, AS-1555-10 cooled autosampler and UV-
1575 UV/Vis detector (Jasco, Essex, UK) linked to a Flow
Scintillation Analyser (500 TR series, Packard, Berks, UK).
A Luna 3 µm C18 (2) column, 150 × 4.6 mm, equipped
with an ODS Security Guard cartridge (Phenomenex,
Cheshire, UK) was utilised. Two mobile phases were used:
phase A: 5% acetonitrile in HPLC grade water with 20 mM
potassium phosphate and 5 mM tetrabutylammonium
dihydrogen phosphate and phase B: 65% acetonitrile in
HPLC grade water with 20 mM potassium phosphate and
5 mM tetrabutylammonium dihydrogen phosphate. The
gradient was linear from 100% phase A to 100% phase B
over 15 min. The flow rate was 1 ml/min and the injection
volume was 100 µl. This was mixed with Ultima-Flo M
scintillation fluid (Packard) and passed through the Flow
Scintillation Analyser for radioactive analysis. The data
was acquired and stored with a Flo-One data acquisition
system (Packard).
Octanol-saline partition coefficient
An octanol-saline partition coefficient was determined for
[3H]PMPA. For this 0.75 ml phosphate buffered saline
(pH 7.4) containing [3H]PMPA was added to a microcen-
trifuge tube with 0.75 ml octanol and vortexed. This was
then centrifuged for 5 min (1000 g 4°C) and triplicate
100 µl samples of the upper phase (octanol) and lower
phase (saline) were taken for radioactive scintillation
counting. The octanol-saline partition coefficient (mean
radioactivity in octanol samples/mean radioactivity in
saline samples) of [3H]PMPA was determined in triplicate
and reported as the mean ± the standard error of the
mean.
Capillary depletion analysis of [3H]PMPA and D-[14C]manni- tol perfused cerebrum samples Figure 3
Capillary depletion analysis of [3H]PMPA and D-[14C]manni-
tol perfused cerebrum samples. Each point represents mean 
± S.E.M., n = 3–6. There were no significant differences 
between the distribution of [3H]PMPA and D-[14C]mannitol 
in the whole brain homogenate, the brain parenchyma 
(supernatant) or the cerebral capillary endothelial cell 
enriched pellet at any time point. Accumulation in the pellet 
and supernatant fractions does not equal the uptake meas-
ured in the homogenate because all the data was standard-
ized by weight. It is estimated that the cerebral capillary 
endothelial cell component only represents approximately 
0.1% of the whole brain homogenate.
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Chemicals
(9-[9(R)-2-(phosphonomethoxy)propyl]adenine, [ade-
nine-2,8-3H] ([3H]PMPA, specific activity 12.5 Ci/mmol),
D-[14C]mannitol (specific activity 53 mCi/mmol) and
unlabelled PMPA (MW 287.2) were purchased from
Moravek Biochemicals Inc (California, USA) and stored at
-20°C, as recommended by the manufacturers. All other
chemicals were bought from Sigma Chemical Company
(Dorset, UK).
Results
Entry into brain and pituitary
The uptake data for [3H]PMPA and D-[14C]mannitol
measured over various perfusion times into the different
regions of the CNS is illustrated in Fig. 2. The uptake of
radiolabeled PMPA into the cerebrum ranged from 0.3 ±
0.1 ml/100 g at 2.5 min to 3.2 ± 0.2 ml/100 g at 30 min.
The uptake of the vascular space marker molecule, D-
[14C]mannitol, was 0.5 ± 0.1 ml/100 g at 2.5 min and 2.9
± 0.5 ml/100 g at 30 min. The uptake of [3H]PMPA was
not significantly greater than that measured for D-
[14C]mannitol into this region at any time point (paired
Student's  t-test). The uptake of [3H]PMPA and D-
[14C]mannitol into the cerebellum at 2.5 min was 0.3 ±
0.1 and 0.4 ± 0.1 ml/100 g, respectively, and at 30 min
was 4.2 ± 0.4 and 3.7 ± 0.5 ml/100 g, respectively. The
[3H]PMPA and D-[14C]mannitol cerebellum values were
not significantly different from each other at any time
point (paired Student's t-test). Similarly, the uptake of
radiolabeled PMPA and mannitol into the pituitary gland
were not significantly different from each other at any
time point (paired Student's t-test).
Entry into choroid plexus and CSF
The accumulation of [3H]PMPA within the choroid plexus
tissue was significantly greater than D-[14C]mannitol at
10, 20 and 30 min (Fig. 2, P < 0.001, paired Student's t-
test or Wilcoxon signed rank test, as appropriate). The
movement of [3H]PMPA into the CSF was also signifi-
cantly greater than that measured for D-[14C]mannitol at
30 min (P < 0.05, paired Student's t-test), but not at any
other time point.
Capillary depletion analysis
Capillary depletion analysis of cerebrum samples from
perfused brains showed that there was no significant dif-
ference between [3H]PMPA and D-[14C]mannitol in the
whole tissue homogenate, parenchyma (supernatant) or
the cerebral capillary cell enriched pellet at any of the time
points (Fig. 3).
Entry in the presence of inhibitors
There was no difference in the movement of [3H]PMPA
into the cerebrum, cerebellum, pituitary, choroid plexuses
or CSF in the presence of the tested anti-HIV drugs and the
The CNS uptake of [3H]PMPA in the presence of unlabelled  PMPA, antiretroviral drugs and probenecid at a perfusion  time of 20 min Figure 4
The CNS uptake of [3H]PMPA in the presence of unlabelled 
PMPA, antiretroviral drugs and probenecid at a perfusion 
time of 20 min. The cerebrum, cerebellum, pituitary and 
choroid plexuses values of [3H]PMPA were corrected for 
vascular space or extracellular space, as measured by D-
[14C]mannitol. The CSF uptake of [3H]PMPA is uncorrected 
for D-[14C]mannitol, as in this tissue it represents a paracel-
lular permeability marker molecule. The uptake of D-
[14C]mannitol in the presence of any of the additional drugs 
was not significantly different to that achieved in their 
absence (control) and demonstrates that at these concentra-
tions of unlabelled drugs the integrity of the barriers is main-
tained. The presence of these additional drugs also did not 
significantly affect the distribution of [3H]PMPA. Each time 
point represents mean ± S.E.M., n = 3–7.
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broad spectrum efflux inhibitor, probenecid (one-way
ANOVA or Kruskal-Wallis one-way ANOVA on ranks, as
appropriate, Fig. 4). There was also no significant differ-
ence between the values achieved for the distribution of
D-[14C]mannitol into any of the CNS regions in the pres-
ence of the tested drugs, data not shown.
Octanol-saline partition coefficient
The octanol-saline partition coefficient for [3H]PMPA was
0.0134 ± 0.00003 (n = 3).
Stability of [3H]PMPA in plasma
HPLC/radio detector analysis was performed on the arte-
rial inflow and venous outflow at 5 and 25 min perfusion
times taken from [3H]PMPA brain perfusion experiments.
The majority of the radioactivities in these plasma sam-
ples were eluted at approximately 7.7 min (Fig. 5). This
retention time is consistent with that for the PMPA stand-
ard and confirms that the majority of the radioactivity
present in the cerebral circulation was intact radiolabeled
PMPA.
Discussion
Uptake of [3H]PMPA into CNS tissues
PMPA was used in this study as it is the molecular form of
the nucleotide reverse transcriptase inhibitor (NtRTI) in
the circulation and thus would be the form exposed to the
luminal surfaces of the blood-brain and blood-CSF inter-
faces. In this present study the uptake of intact [3H]PMPA
into the cerebrum, cerebellum and cerebral capillary
endothelial cell enriched pellet was no greater than that
measured for the marker molecule, D-[14C]mannitol
(Figs. 2, 3 and 4). Radiolabeled mannitol transport across
the BBB has been investigated in an earlier study where
rats were dosed intravenously and the brain uptake of D-
[3H]mannitol was corrected for vascular space using radi-
olabeled indium as a marker of blood plasma space [26].
Low levels of D-[3H]mannitol were measured in the brain
parenchyma with values being 1.2% of plasma concentra-
tions after 10 min, rising to 3.3% after 4 h. Work by Sisson
and Oldendorf demonstrated that the initial uptake (0–
10 min) of D-[3H]mannitol into rat brain is rapid, and
this is the result of mannitol entering a small rapidly
equilibrating brain space, suggested to be the area
between the capillary endothelium and the neurological
lining of the capillary, or the capillary endothelium itself
[26]. This rapid uptake is followed by slow steady uptake
into the brain compartment. Hence within the timescale
of the experiments described in this current study, D-
[14C]mannitol uptake into the brain mainly represents
vascular space within this tissue, plus slow paracellular
diffusion between the BBB endothelial cells. Thus the
results show that the integrity of the brain barriers was
maintained since the D-[14C]mannitol values were similar
to those previously reported by Sisson and Oldendorf for
the rat [26] and by our own research group in the guinea
pig [27]. Hence, D-[14C]mannitol uptake provides a base-
line to which PMPA uptake into the brain can be com-
pared. It is important to note that PMPA is not highly
bound to proteins with 99% remaining unbound in the
plasma [6], and this is also indicated in this present study
when an excess of unlabelled PMPA failed to change the
CNS distribution of [3H]PMPA. This fact, together with
the uptake data indicates that [3H]PMPA has a very lim-
ited ability to cross the BBB. This is certainly linked to the
hydrophilic nature of PMPA as measured by its low octa-
nol-saline partition coefficient of 0.013, which is higher
than the coefficient previously measured for D-[14C]man-
nitol (0.002 ± 0.0004 [25]), but lower than other non-
BBB penetrating molecules such as urea (0.03 [28]).
Another interesting observation is that the distribution of
[3H]PMPA into the pituitary gland, although much greater
than into brain tissue, was not significantly different to
HPLC-radio detector analysis of arterial inflow and venous  outflow samples taken after 5 and 25 minutes of perfusion  with [3H]PMPA showing that the majority of the radioactivity  present in the cerebral circulation was intact radiolabeled  PMPA Figure 5
HPLC-radio detector analysis of arterial inflow and venous 
outflow samples taken after 5 and 25 minutes of perfusion 
with [3H]PMPA showing that the majority of the radioactivity 
present in the cerebral circulation was intact radiolabeled 
PMPA.
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that observed for D-[14C]mannitol. The pituitary gland
consists of two distinct parts, the posterior and the ante-
rior pituitary. The neural lobe of the pituitary (part of the
posterior pituitary) lies outside the BBB and thus the cap-
illaries in this region are more permeable than the BBB
capillaries, allowing the free exchange of circulating sub-
stances between the blood and pituitary gland [29]. In the
pituitary gland, D-[14C]mannitol would be able to cross
the capillary endothelium freely by passing between the
cells, and hence act like a paracellular permeability
marker molecule. The lack of a difference between this
marker molecule and the test NtRTI in the pituitary gland
would suggest that PMPA, acts like D-[14C]mannitol, and
is also crossing the capillary endothelium paracellularly in
the pituitary gland. In contrast to this, the choroid plexus
tissue had a significantly greater accumulation of
[3H]PMPA compared to the simultaneously measured D-
[14C]mannitol. The nature of the choroid plexus capillar-
ies allows mannitol to penetrate into the stromal space,
however, mannitol does not gain access to the cellular
compartment of the choroid plexus [30]. Overall, the
results of this present study would suggest that [3H]PMPA
is able to cross the cell membranes of the choroid plexus.
It is not possible to determine if the PMPA is accumulat-
ing in the choroid plexus endothelium or the epithelium
or in both, but together with the data illustrated in Fig. 3
and the low lipophilicity of PMPA, these results suggest
that a transport system may be involved in the movement
of PMPA into the choroid plexus. Another interesting
observation is that [3H]PMPA does reach the CSF in the
cisterna magna. As there was no detectable movement of
[3H]PMPA across the BBB, this would suggest that it has
come from movement across the blood-CSF barrier, prin-
cipally the choroid plexuses. The tight junctions at the
choroid plexuses are considered to be 'leakier' and hence
more permeable, than the capillary endothelium, due to
the differences in the continuity of the tight junctions
between these two vascular-CNS interfaces [31,32]. Thus
drugs have previously been seen to cross the blood-CSF
barrier, but not the BBB [33]. The higher movement of
[3H]PMPA into the CSF compared with D-[14C]mannitol
after 30 min of vascular perfusion could also indicate that
[3H]PMPA is crossing transcellularly, in addition to para-
cellularly. This is also confirmed by the presence of
[3H]PMPA within the cells of the choroid plexus tissue as
measured by its higher accumulation than D-[14C]manni-
tol in this compartment. Overall this would indicate that
PMPA would have rapid access to the HIV infected
perivascular and meningeal macrophages [34,35], but it is
unlikely to be able to eradicate virus in the microglia,
which together with the perivascular macrophages are
thought to be the major populations of infected cells
within the CNS [36-39].
Possible involvement of transporters
Drug movement across the blood-brain and blood-CSF
barriers can occur by diffusion or through the action of
transport systems. Several transport systems exist at the
brain-barriers and can facilitate the movement of mole-
cules into and out of the CNS. As there was differential
handling of [3H]PMPA and D-[14C]mannitol at the level
of the choroid plexuses compared with the cerebral capil-
lary endothelium, some form of transporter involvement
is suggested. This is likely to be at the choroid plexus due
to the hydrophilic nature of PMPA and the lack of any sig-
nificant accumulation of PMPA by the cerebral capillary
endothelial cell enriched pellet. Further studies investi-
gated if we could detect any saturable transporter for
PMPA using an excess concentration (50 µM) of unla-
belled PMPA. This concentration was chosen based on the
free tenofovir plasma Cmax of 0.8–1.3 µM measured after
a therapeutic dose of the tenofovir pro-drug had been
administered to HIV patients [3]. However, none of the
tissues we examined, including the choroid plexus, indi-
cated the presence of a high affinity transporter for PMPA.
It is known that [3H]PMPA is efficiently transported by the
human renal organic anion transporter (OAT1) [40].
PMPA also shows a moderate inhibition of renal hOAT3
with a half-saturation transport constant (Km) of 3.3 mM
[41]. Thus hOAT3 is a low affinity transporter for PMPA,
where as hOAT1 appears to a function as a high-affinity
transporter with a Km of 34 µM. OAT1 has been detected
in the brains of humans, rats and mice, and OAT1 is
expressed in the choroid plexus of mice and rats [42]
albeit at low levels [43,44], where it is understood to be
located on the apical membrane of the epithelial cells and
can function to efflux organic anions from the CSF
[42,45]. Although there is no direct evidence for the
expression of OAT1 at the BBB, it is suggested that the
observed efflux of certain substances known to be OAT1
substrates (including AZT and benzylpenicillin) from
brain to blood, indicates that the presence of OAT1 at the
BBB is likely [46]. OAT3 is expressed in the human and rat
CNS [47,48]. In the brain, OAT3 is localized at the apical
membrane of the choroid plexus [42,49] and at the ablu-
minal membrane of capillary endothelial cells [50]. PMPA
has also been shown to be a substrate for multidrug resist-
ance protein 2 (MRP2) in cell lines transfected with the
transporters [41]. Probenecid, as used in this study, is a
broad inhibitor of organic anion transport, and is known
to inhibit the members of the OAT family, as well as the
organic anion transporter polypeptide (OATP/oatp) and
MRP families. However, there was no detectable interac-
tion of [3H]PMPA with these transporters as determined
by the absence of a significant affect on CNS distribution
when probenecid was present in the perfusion medium.
An interesting aspect of the use of transporters by anti-HIV
drugs is that certain combinations of anti-HIV drugs couldCerebrospinal Fluid Research 2006, 3:1 http://www.cerebrospinalfluidresearch.com/content/3/1/1
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interact for transport at the brain barriers. For example,
the concentration of 2'3'-dideoxyinosine (ddI) in the
guinea-pig choroid plexus was altered in the presence of
the other NRTIs, abacavir, (-) -β-L-2'3'-dideoxy-3'-thiacy-
tidine (3TC) and AZT [51]. In addition, ritonavir accumu-
lation by the perfused choroid plexus was significantly
reduced by nevirapine and abacavir [27]. This could ulti-
mately result in sub-therapeutic concentrations of drugs
within the brain/choroid plexus/CSF, which would allow
viral replication to continue and drug resistant strains of
HIV to be selected. A clear understanding of the use of
transport mechanisms by the anti-HIV drugs could clearly
aid in the design of more effective drug regimens. For this
reason, a series of cross-competition studies were also car-
ried out with other anti-HIV drugs in the artificial plasma.
There was no significant change in the CNS accumulation
of radiolabeled PMPA in the presence of AZT, D4T,
abacavir or ddC. Previous studies have also found no evi-
dence for an antagonistic pharmacokinetic/pharmacody-
namic interaction between PMPA and abacavir [52-55].
However, unexpected early virological failure has been
seen with the once-daily triple-NRTI combinations of ddI/
3TC/PMPA and abacavir/3TC/PMPA [56], but this is not
seen when these agents are also used with a protease
inhibitor [6,57]. Overall these results of drug combina-
tion experiments suggest that PMPA should function
effectively as part of many anti-HIV combination thera-
peutic regimens.
Conclusion
PMPA has been shown to cross the blood-CSF barrier and
reach the CSF, but it cannot cross the BBB to reach deep
brain sites. Overall this would suggest that it should only
be included in a regimen with anti-HIV drugs already
proven in their capacity to prevent or alleviate the neuro-
logical problems associated with HIV infection or AIDS.
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